US 12,240,853 B2
Compounds useful in HIV therapy
John F. Miller, Research Triangle Park, NC (US); and Emile Johann Velthuisen, Research Triangle Park, NC (US)
Assigned to GlaxoSmithKline Intellectual Property (No.2) Limited, (GB)
Filed by GlaxoSmithKline Intellectual Property (No.2) Limited, Stevenage (GB)
Filed on May 4, 2020, as Appl. No. 16/865,678.
Claims priority of provisional application 62/814,316, filed on Mar. 6, 2019.
Prior Publication US 2023/0174534 A1, Jun. 8, 2023
Int. Cl. C07D 473/34 (2006.01); A61K 9/00 (2006.01); A61K 31/70 (2006.01); A61K 45/06 (2006.01); A61P 31/08 (2006.01); A61P 31/18 (2006.01); C07D 487/04 (2006.01); C07H 19/16 (2006.01); C07H 19/173 (2006.01)
CPC C07D 473/34 (2013.01) [A61K 9/0019 (2013.01); A61K 31/70 (2013.01); A61K 45/06 (2013.01); A61P 31/18 (2018.01); C07D 487/04 (2013.01); C07H 19/16 (2013.01); C07H 19/173 (2013.01)] 16 Claims
 
1. A compound having the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.